VEGF News and Research RSS Feed - VEGF News and Research

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
NEI-funded study analyzes outcomes of anti-VEGF therapy for AMD

NEI-funded study analyzes outcomes of anti-VEGF therapy for AMD

In a study of nearly 650 people with the eye disease age-related macular degeneration (AMD), half still had vision 20/40 or better, typically good enough to drive or to read standard print, after five years of treatment with anti-VEGF drugs that are injected into the eye. The authors of the study, funded by the National Eye Institute (NEI) at the National Institutes of Health, say those outcomes would have been unimaginable about 10 years ago, prior to the drugs' availability. [More]
Scientists find way to reduce need for secondary cataract surgery

Scientists find way to reduce need for secondary cataract surgery

Scientists at the University of East Anglia may have found a way to prevent complications from surgery to treat cataract - the world's leading cause of blindness. [More]
New study explores mechanisms that control size, shape of tubular organ systems

New study explores mechanisms that control size, shape of tubular organ systems

A new study from the group of Holger Gerhardt in collaboration with Katie Bentley's Lab addresses a long standing question in the wider field of developmental biology and tissue patterning in general, and in the vascular biology field in particular: 'What are the fundamental mechanisms controlling size and shape of tubular organ systems'. [More]
Scientists reveal mechanism involved in regulation of lymphangiogenesis

Scientists reveal mechanism involved in regulation of lymphangiogenesis

After an injury to tissues, such as in organ transplantation, the body grows new lymphatic vessels in a process known as lymphangiogenesis. A new study in Nature Communications reveals a mechanism involved in the regulation of this process, specifically in corneal transplants and infectious eye disease. [More]
Inserm study reveals potential of secondary system to improve heart function

Inserm study reveals potential of secondary system to improve heart function

Heart failure affects over one million people in France. Although the blood system is the first to have been explored for the purpose of improving heart function, a study by Inserm has revealed the potential of a secondary system that had previously received scant attention. [More]
Increased expression of VEGF-A promotes three common aging-related eye conditions

Increased expression of VEGF-A promotes three common aging-related eye conditions

A Massachusetts General Hospital investigator has found that increased expression of the angiogenic factor VEGF-A promotes three common aging-related eye conditions - both versions of age-related macular degeneration (AMD) and also cataracts - in an animal model. [More]
Study identifies genetic differences in kidney tumors of African-Americans

Study identifies genetic differences in kidney tumors of African-Americans

A University of North Carolina Lineberger Comprehensive Cancer Center-led study has identified genetic differences in tumors of African-Americans with the most common type of kidney cancer compared with whites. [More]
Anticancer drug restores hearing in neurofibromatosis patients

Anticancer drug restores hearing in neurofibromatosis patients

In a small clinical study with an anticancer drug that halts blood vessel growth, a handful of people with neurofibromatosis type 2 (NF2) and hearing loss had restoration of hearing. [More]
Drugs to help energy-starved photoreceptors offers new avenue for treating AMD , MacTel

Drugs to help energy-starved photoreceptors offers new avenue for treating AMD , MacTel

New research from Boston Children's Hospital could potentially change how doctors approach two blinding diseases: 'Wet' age-related macular degeneration (AMD), the leading cause of blindness in the elderly, and macular telangiectasia (MacTel). [More]
NK cells produce VEGF-A that promotes tumor growth

NK cells produce VEGF-A that promotes tumor growth

The immune system protects the body against cancer cells. The Elimination of cancer cells is an important task of NK cells. For NK cells to function properly, they require the activator STAT5. [More]
MGH study reveals effects of obesity on pancreatic and breast cancer

MGH study reveals effects of obesity on pancreatic and breast cancer

Massachusetts General Hospital investigators may have uncovered a novel mechanism behind the ability of obesity to promote cancer progression. In their report published online in the journal Clinical Cancer Research, the research team describes finding an association between obesity and an overabundance of a factor called PlGF (placental growth factor) and that PlGF's binding to its receptor VEGFR-1, which is expressed on immune cells within tumors, promotes tumor progression. [More]
CHLA researchers develop novel model for studying neonatal lung disorder

CHLA researchers develop novel model for studying neonatal lung disorder

Investigators at The Saban Research Institute of Children's Hospital Los Angeles have created a novel model for studying a lung disorder of newborn babies. Their study, published in PLOS ONE on February 10, describes the first model that allows investigators to consider the chronic effects of developmental lung disease. [More]
Combined MRI and ultramicroscopy toolkit could help study vessel growth in glioma models in more detail

Combined MRI and ultramicroscopy toolkit could help study vessel growth in glioma models in more detail

Stopping the growth of blood vessels in tumours is a key target for glioblastoma therapies, and imaging methods are essential for initial diagnosis and monitoring the effects of treatments. While mapping vessels in tumours has proven a challenge, researchers have now developed a combined magnetic resonance imaging (MRI) and ultramicroscopy 'toolkit' to study vessel growth in glioma models in more detail than previously possible. [More]
Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib versus everolimus trial highlights non-clear cell RCC patient response heterogeneity

Sunitinib offers significantly longer progression-free survival than everolimus for patients with metastatic non-clear cell renal cell carcinoma, phase II trial results indicate, but treatment effect appears to depend upon key patient characteristics. [More]
Combining nanomedicine with two anticancer treatments could improve outcomes for pancreatic cancer patients

Combining nanomedicine with two anticancer treatments could improve outcomes for pancreatic cancer patients

A nanoparticle drug-delivery system that combines two complementary types of anticancer treatment could improve outcomes for patients with pancreatic cancer and other highly treatment-resistant tumors while decreasing toxicity. [More]
First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

First patient enrolled in ThromboGenics' Phase II CIRCLE study of ocriplasmin in NPDR patients

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease, today announces that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR). [More]
MiMedx Group agrees to buy Stability Biologics

MiMedx Group agrees to buy Stability Biologics

MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it has signed a definitive agreement to acquire Stability Inc., d/b/a Stability Biologics, a provider of human tissue products to surgeons, facilities and distributors serving the surgical, spine and orthopedics sectors of the healthcare industry. [More]
Scientists identify 52 genetic variations associated with age-related macular degeneration

Scientists identify 52 genetic variations associated with age-related macular degeneration

In one of the latest examples of precision medicine, teams of geneticists from nine countries, involving more than 100 scientists, analyzed the genes of more than 33,000 individuals in the hope of finding genetic variations responsible for age-related macular degeneration (AMD), the leading cause of vision loss among people age 50 or older. [More]
Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Mirati announces initiation of glesatinib Phase 2 clinical trial in NSCLC patients

Mirati Therapeutics, Inc. today announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced. The Company also announced that "glesatinib" is the proposed generic name for MGCD265. [More]
Advertisement
Advertisement